Bridges Investment Management Inc. grew its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 40.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 2,347 shares of the medical instruments supplier’s stock after acquiring an additional 672 shares during the period. Bridges Investment Management Inc.’s holdings in Becton Dickinson and were worth $503,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Balyasny Asset Management LLC lifted its holdings in shares of Becton Dickinson and by 229.8% in the second quarter. Balyasny Asset Management LLC now owns 120,618 shares of the medical instruments supplier’s stock valued at $23,534,000 after purchasing an additional 213,564 shares in the last quarter. Salem Investment Counselors Inc. lifted its holdings in shares of Becton Dickinson and by 4.2% in the second quarter. Salem Investment Counselors Inc. now owns 2,629 shares of the medical instruments supplier’s stock valued at $513,000 after purchasing an additional 105 shares in the last quarter. Zurich Insurance Group Ltd FI lifted its holdings in shares of Becton Dickinson and by 27.9% in the second quarter. Zurich Insurance Group Ltd FI now owns 38,199 shares of the medical instruments supplier’s stock valued at $7,453,000 after purchasing an additional 8,342 shares in the last quarter. L & S Advisors Inc purchased a new stake in shares of Becton Dickinson and in the second quarter valued at $6,021,000. Finally, Boston Common Asset Management LLC purchased a new stake in shares of Becton Dickinson and in the second quarter valued at $205,000. Institutional investors own 75.56% of the company’s stock.
Becton Dickinson and Co (BDX) opened at $222.87 on Monday. Becton Dickinson and Co has a one year low of $175.66 and a one year high of $248.39. The company has a quick ratio of 0.93, a current ratio of 1.54 and a debt-to-equity ratio of 1.04. The firm has a market cap of $51,130.00, a price-to-earnings ratio of 170.13, a PEG ratio of 1.59 and a beta of 1.12.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be paid a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.35%. The ex-dividend date of this dividend is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio (DPR) is presently 229.01%.
A number of analysts have recently issued reports on BDX shares. Zacks Investment Research lowered Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Friday, January 12th. Morgan Stanley increased their target price on Becton Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Royal Bank of Canada restated a “hold” rating and issued a $210.00 target price on shares of Becton Dickinson and in a report on Wednesday, October 25th. Stifel Nicolaus restated a “buy” rating and issued a $245.00 target price on shares of Becton Dickinson and in a report on Friday, November 3rd. Finally, KeyCorp started coverage on Becton Dickinson and in a report on Friday, January 5th. They issued an “overweight” rating and a $260.00 target price for the company. Four analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $237.27.
In other news, Director Timothy M. Ring sold 269,661 shares of the company’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $217.82, for a total value of $58,737,559.02. Following the transaction, the director now directly owns 295,753 shares of the company’s stock, valued at $64,420,918.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.00% of the company’s stock.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.